789results about "Muscular disorder" patented technology

A composition contains one or more aromatic amino acids and optionally vitamin B6. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be in a form of a powder, a powdered stick, a capsule or a solution. The composition can be administered to an individual in need thereof orally or intravenously for preventing and / or treating sarcopenia, a loss of and / or improving skeletal muscle mass, lean muscle mass, skeletal muscle strength and / or skeletal muscle function.

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

The present application relates to a pharmaceutical composition comprising an NRF2 agonist and borneol, both of which synergize in a specific molar ratio range, enhance the overall anti-inflammatory and antioxidant biological activity of the drug, improve the oral bioavailability and target tissue distribution of the drug, inhibit the off-target side effects of the NRF2 agonist, and significantly improve the effectiveness and safety of the drug.

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

The present invention relates to spinal cord regeneration therapy. In one aspect, the present disclosure provides administration of an effective amount of at least four herb components, Polygalae (Polygala tenuifolia Willd.), Astragali (Astragalus membranaceus (Fisch.) Bunge), Ligusticum Chuanxiong, and Angelica sinensis (Oliv.), their roots or rhizomes, or extracts thereof, to a subject having a spinal cord injury. In other aspects, the present disclosure provides in vitro and in vivo methods for determining the effectiveness of drugs and drug combinations, and the effective amount thereof necessary for treating spinal cord injury.

The present application relates to the field of biotechnology and the field of RNA technology. In particular, the present application relates to an engineered tRNA, isolated nucleic acid molecules expressing the same, compositions comprising the same, delivery compositions and host cells. The present application also relates to their use in the manufacture of a medicament and a formulation.

The present invention relates to variable domains (VHHs) of camelid heavy chain molecules that bind to TfR, conjugate compounds containing such VHH molecules, and their use for, for example, transporting molecules for pharmaceutical purposes to cells and organs in pathological conditions in the CNS or PNS, including cancer.

The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention be can easily store and distribute. AND it was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.

This invention relates to compounds having the ability to regulate / stimulate / induce, particularly induce, the degradation of target proteins. Such target proteins may be proteins involved in diseases such as cancer, metabolic disorders, infectious diseases, and / or neurological disorders. This invention also relates to the use of compounds and compositions as pharmaceuticals, and pharmaceutical compositions comprising these compounds. (I)

Provided are modified botulinum neurotoxin type A2, and a preparation method therefor and a use thereof. The modified botulinum neurotoxin type A2 comprises an LC domain and an HN domain, wherein a structural unit enabling the LC domain and the HN domain to undergo controllable cleavage under a predetermined condition is artificially set between the LC domain and the HN domain; optionally, one or more specific protease cleavage sites are comprised between the last cysteine at the C‑terminus of the LC domain and the first cysteine at the N‑terminus of the HN domain.

This invention discloses a sustained-release hydrogel heat patch made from essential oil compositions and its preparation method, belonging to the technical field of external patches made from essential oil compositions. It consists of a sustained-release hydrogel layer of plant essential oil compositions and a constant-temperature heat-containing patch layer. The essential oil composition is adsorbed into the pores of nanoporous starch microspheres, forming nanospheres carrying the essential oil composition, which are then dispersed in a pithiolic acid-chitosan composite hydrogel matrix to achieve long-lasting aromatic release. The essential oil composition contains pine needle oil and ginger oil to warm the meridians and promote blood circulation; frankincense oil and angelica oil to invigorate blood and remove blood stasis; costus root oil and cinnamon oil to regulate qi and relieve pain; and artemisia oil and clove oil to guide transdermal absorption. These components work synergistically with the constant-temperature heat-containing patch layer, providing advantages such as precise temperature control, sustained-release effect, safe and comfortable use, and a warm and rich aroma. It has significant application value in the adjuvant treatment and rehabilitation of sports injuries.

This invention provides the application of triptolide in the preparation of drugs for treating microglial inflammation-related neuroimmunological disorders. Experiments show that triptolide significantly inhibits the expression, migration, phagocytosis, and morphological activation of microglial inflammatory factors, and exerts an anti-microglial inflammatory effect in animal models. Through DARTS technology combined with siRNA screening, ACOX1 was identified as its key target, and the direct binding between the two was verified by CETSA, SPR, and molecular docking.

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

Disclosed in the present invention is a deuterated 1,2,4-triazole Apelin receptor agonist, as shown in the following formula I. The present invention relates to a deuterated 1,2,4-triazole Apelin receptor agonist and a pharmaceutical composition thereof, and a use.

The present invention relates to Ruminococcaceae species and a new strain of Luminococcus lactaris for use alone or in combination in the treatment and prevention of memory decline in an individual, particularly memory decline of aging or Alzheimer's disease-related origin. The present invention also provides a composition, particularly an oral composition, comprising a Ruminococcaceae species and a Luminococcus lactaris strain, and uses thereof.

Disclosed are conjugates of an oligonucleotide and a peptide covalently bonded or linked to the oligonucleotide via a linker that target a human dystrophin gene, compositions including the same, and methods of use thereof.

The application belongs to the field of food processing and biomedical technology, and discloses a preparation method of a salty taste enhancing peptide-naringenin compound and application of the compound in improving cognitive decline. The compound is prepared by compounding salty taste enhancing peptides from soft-shelled turtle eggs and naringenin at a ratio of 20-150:1 (w:w). The preparation process comprises the following steps: soft-shelled turtle egg enzymolysis, ultrafiltration, freeze-drying to obtain salty taste enhancing peptides, mixing the salty taste enhancing peptides with a naringenin solution, concentration, and freeze-drying. The compound has good stability, salty taste enhancing and antioxidant activities, can reduce the use of salt and maintain salty taste. The compound can improve cognitive decline and anxiety caused by aging and diabetes, improve autonomous activity, memory and social skills, strengthen physical fitness, protect nerve cells and skeletal muscles, maintain brain tissue health, and can be applied to the preparation of related preparations for improving cognitive decline.

The present disclosure describes compounds of Formula (I), as well as salts thereof, and pharmaceutical compositions comprising the compounds, which modulate the activity of the potassium channels, specifically Kv7.2-7.5 channels These compounds that modulate potassium channels, which are useful in the treatment of disorders, such as neural diseases, neural degenerative diseases, neural behavioral diseases, muscle movement diseases, neuroinflammatory diseases, addiction and substance use disorders, as well as for pain management.

The process provided in this invention transfects primary cells with gene editing reagents using a high-volume gas-permeable cell culture device and a flow-through electroporation device under conditions that improve gene editing performance, cell yield, and drug (DP) quality characteristics for cell therapy applications. As demonstrated in the examples, primary cells edited according to the process provided herein achieved improved double-strand break (DSB) formation rates, increased frequency of homology-directed repair (HR) and non-homologous end joining (NHEJ) combinations, increased frequency of bi-allelic and mono-allelic HR events, improved cell viability, proliferative capacity, and cell fitness after gene editing, and reduced manufacturing time.

The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and / or an immune-related disorder.

One aspect of the present invention is a compound of formula (I) for use as a medicament [Formula 1] JPEG2023528073000334.jpg41120[In the formula, Ring A is a 5- or 6-membered aromatic or heteroaromatic ring, and the aromatic or heteroaromatic ring is selected from the group consisting of F, Cl, Br, I, CN, alkoxy, NR 11 R 11 , OH, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, wherein the aryl and heteroaryl substituents may further be selected from F, Cl, Br, I, CN, alkoxy, NR 11 R 11 substituted with one or more substituents each independently selected from , OH, alkyl, haloalkyl, and aralkyl; Y is C=N-OH and CR 10 R 10 ' is selected from R 10 and R 10 each ' is independently selected from H, F, alkyl, and haloalkyl; R1, R4, and R5 are each independently selected from H, F, Cl, Br, and I; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, methoxy, and haloalkyl; R 11 and R 11 ' are each independently H, alkyl, haloalkyl, COR 12 , and SO2R 13 Selected from R 12 and R 13 and R are both alkyl], or a pharmaceutically acceptable salt or solvate thereof. A further aspect of the present invention relates to compounds of formula (I) for use in the fields of immuno-oncology, immunology and related applications, and to compounds of formula (I) per se.

The present invention relates to the treatment or prevention of conditions linked to reduced muscle mass or reduced muscle protein synthesis rate. A subject matter of the invention is a composition comprising complexes of whey protein micelles and pectin for use in the treatment or prevention of a condition selected from the group consisting of sarcopenia, muscle atrophy and negative nitrogen balance. Further aspects of the invention relate to the non-therapeutic use of a composition comprising complexes of whey protein micelles and pectin and a food composition.

This embodiment is directed to a method of using a glycine transporter inhibitor, such as a GlyT1 inhibitor, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a pharmaceutical composition thereof, for preventing or treating hepatic porphyria and related syndromes. In certain embodiments, the disclosure provides a method of treating hepatic porphyria in a subject, the method comprising administering to the subject a pharmaceutical composition comprising one or more glycine transporter 1 (GlyT1) inhibitors or pharmaceutically acceptable salts thereof, or one or more prodrugs of a GlyT1 inhibitor or salts thereof.

The present invention provides, inter alia, apelin receptor agonists having increased half-life, reduced desensitization, improved apelin receptor signaling properties (e.g., bias of G a signaling over arrestin signaling), enhanced stability, and / or enhanced binding to apelin receptors.

The present application relates to compounds of formula (B1A), (B1B), (B1C) JPEG2025527459000149.jpg87170 or a salt, solvate, hydrate, polymorph, tautomer, racemate or stereoisomer thereof, pharmaceutical compositions containing such compounds and compounds for use as a medicament, particularly for use in the treatment of neurodegenerative disorders such as Alzheimer's disease.